Literature DB >> 7868240

Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e.

G T Keusch1, M Jacewicz, D W Acheson, A Donohue-Rolfe, A V Kane, R H McCluer.   

Abstract

We reexamined the binding specificity of the Shiga-like toxin variant associated with porcine edema disease, SLT2e, which is reported to be more cytotoxic for Vero cells than for HeLa cells, by using receptor-deficient cells and a liposomal insertion system for purified glycolipids. We found that SLT2e preferentially uses globotetraosylceramide as a receptor but can also cause cytotoxicity by using globotriaosylceramide, the SLT2 receptor. We conclude that the differential cytotoxicity of SLT2e on HeLa and Vero cells is a function of both the receptor preference of the toxin and the specific glycolipid content of the target cells being used.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7868240      PMCID: PMC173124          DOI: 10.1128/iai.63.3.1138-1141.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  8 in total

Review 1.  Shiga and Shiga-like toxins.

Authors:  A D O'Brien; R K Holmes
Journal:  Microbiol Rev       Date:  1987-06

2.  One step high yield affinity purification of shiga-like toxin II variants and quantitation using enzyme linked immunosorbent assays.

Authors:  D W Acheson; M Jacewicz; A V Kane; A Donohue-Rolfe; G T Keusch
Journal:  Microb Pathog       Date:  1993-01       Impact factor: 3.738

3.  Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine.

Authors:  D L Weinstein; M P Jackson; J E Samuel; R K Holmes; A D O'Brien
Journal:  J Bacteriol       Date:  1988-09       Impact factor: 3.490

4.  Globotetraosylceramide is recognized by the pig edema disease toxin.

Authors:  S DeGrandis; H Law; J Brunton; C Gyles; C A Lingwood
Journal:  J Biol Chem       Date:  1989-07-25       Impact factor: 5.157

5.  Pathogenesis of Shigella diarrhea: XVII. A mammalian cell membrane glycolipid, Gb3, is required but not sufficient to confer sensitivity to Shiga toxin.

Authors:  M S Jacewicz; M Mobassaleh; S K Gross; K A Balasubramanian; P F Daniel; S Raghavan; R H McCluer; G T Keusch
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

6.  Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase.

Authors:  J Inokuchi; N S Radin
Journal:  J Lipid Res       Date:  1987-05       Impact factor: 5.922

7.  Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content.

Authors:  A Pellizzari; H Pang; C A Lingwood
Journal:  Biochemistry       Date:  1992-02-11       Impact factor: 3.162

8.  Purification and some properties of a Vero toxin from a human strain of Escherichia coli that is immunologically related to Shiga-like toxin II (VT2).

Authors:  Y Oku; T Yutsudo; T Hirayama; A D O'Brien; Y Takeda
Journal:  Microb Pathog       Date:  1989-02       Impact factor: 3.738

  8 in total
  23 in total

1.  Localization of potential binding sites for the edema disease verotoxin (VT2e) in pigs.

Authors:  T E Waddell; B L Coomber; C L Gyles
Journal:  Can J Vet Res       Date:  1998-04       Impact factor: 1.310

Review 2.  Aglycone modulation of glycolipid receptor function.

Authors:  C A Lingwood
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

3.  Shiga toxin glycosphingolipid receptors of Vero-B4 kidney epithelial cells and their membrane microdomain lipid environment.

Authors:  Daniel Steil; Catherine-Louise Schepers; Gottfried Pohlentz; Nadine Legros; Jana Runde; Hans-Ulrich Humpf; Helge Karch; Johannes Müthing
Journal:  J Lipid Res       Date:  2015-10-13       Impact factor: 5.922

4.  Bimodal Response to Shiga Toxin 2 Subtypes Results from Relatively Weak Binding to the Target Cell.

Authors:  Patrick Cherubin; Dennis Fidler; Beatriz Quiñones; Ken Teter
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

5.  Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide.

Authors:  Steven D Zumbrun; Leanne Hanson; James F Sinclair; James Freedy; Angela R Melton-Celsa; Jaime Rodriguez-Canales; Jeffrey C Hanson; Alison D O'Brien
Journal:  Infect Immun       Date:  2010-08-23       Impact factor: 3.441

6.  Synthesis of an Aminooxy Derivative of the Trisaccharide Globotriose Gb3.

Authors:  Samir Ghosh; Peter R Andreana
Journal:  J Carbohydr Chem       Date:  2014-09-01       Impact factor: 1.667

7.  Translocation of Shiga toxin across polarized intestinal cells in tissue culture.

Authors:  D W Acheson; R Moore; S De Breucker; L Lincicome; M Jacewicz; E Skutelsky; G T Keusch
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

Review 8.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  A Lipidomic Readout of Disease Progression in A Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease.

Authors:  Arun J Sanyal; Tommy Pacana
Journal:  Trans Am Clin Climatol Assoc       Date:  2015

10.  Evaluation of major types of Shiga toxin 2E-producing Escherichia coli bacteria present in food, pigs, and the environment as potential pathogens for humans.

Authors:  Lothar Beutin; Ulrike Krüger; Gladys Krause; Angelika Miko; Annett Martin; Eckhard Strauch
Journal:  Appl Environ Microbiol       Date:  2008-05-30       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.